Technology ❯ Biotechnology ❯ Drug Development
Neoantigen Therapy
Late‑stage success for the personalized vaccine reduces clinical uncertainty for intismeran and has driven a sharp re‑rating of Moderna’s stock while key commercial questions remain.
